Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer

BACKGROUND: The aim of this study was to determine whether early tumor shrinkage (ETS) at 6 weeks after treatment correlates with progression-free survival (PFS) and overall survival (OS) in advanced biliary tract cancer (BTC) patients receiving gemcitabine plus oxaliplatin (GEMOX), with or without...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Jang, Kee-Taek, Lee, Su Jin, Jang, Hye-Lim, Lee, Jeeyun, Park, Se Hoon, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Park, Joon Oh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507321/
https://www.ncbi.nlm.nih.gov/pubmed/26189560
http://dx.doi.org/10.1186/s12885-015-1552-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507321/
https://www.ncbi.nlm.nih.gov/pubmed/26189560
http://dx.doi.org/10.1186/s12885-015-1552-y

Ejemplares similares